Immunotherapy for Nonresponsive Solid Tumors
Name of the Trial
Phase I Study of Interleukin-7 in Patients With Refractory Solid Tumors (NCI-03-C-0152I). See the protocol summary.
Dr. Claude Kasten-Sportes, NCI Center for Cancer Research.
Why This Trial Is Important
Immunotherapy involves stimulating or restoring the body’s immune system to more aggressively fight disease and is one method being investigated to treat many different forms of cancer.
Interleukin-7 (IL-7) is one immunotherapy agent being tested to treat cancer. IL-7 can stimulate tumor-fighting white blood cells (T cells and B cells) to grow. In addition, some animal studies have shown that treatment with IL-7 may cause tumors to shrink.
In this phase I trial, researchers are testing IL-7’s ability to stimulate patients’ white blood cells to kill cancer cells in solid tumors that have not responded to standard therapies. Solid tumors include cancers of body tissues other than the blood, bone marrow, or lymphatic system.
“IL-7 seems to be a very promising immunotherapy agent,” said Dr. Kasten-Sportes. “This trial should provide the knowledge of how to best use IL-7 to improve immunotherapy in the treatment of solid tumors.”
This clinical trial is no longer accepting new patients. To locate other clinical trials for solid tumors, search the NCI database of clinical trials or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The call is toll free and confidential.